Abstract
Recent reports suggest that 52–95% of children with an autism spectrum disorder in the United States are using some form of alternative treatment (Hanson et al. 2007; Harrington et al. 2006; Wong and Smith 2006). One alternative treatment that has been shown to have some potential promise is polyunsaturated fatty acid supplementation (PUFA). PUFAs are naturally occurring lipids that must be taken in through the diet and are critical to the rapidly developing brains of young children (Fernstrom 2000; Horrocks and Farooqui 2004). This pilot study involved a 3-month, prospective, open label, but randomized, parallel groups design of PUFA supplement compared to a healthy, low sugar diet (attention control) for young children with an autism spectrum disorder (ASD). The PUFA for this study was Docoahexanoic Acid (DHA). The PUFA group had ten participants while the control group had 13 participants. Participants in the PUFA took two capsules per day for a daily dose of 400 mg of DHA for 3 months. No clinical gains were realized on any of the behavioral or developmental outcome measures. The statistically significant differences can be accounted for by differences in the two groups at baseline. While no clinical improvements were observed, the omega-3 supplements were well-tolerated. While our results do not support DHA supplementation at 400 mg / day, further inquiry is warranted given the equivocal results among individuals with autism and other developmental disorders. Our study was limited by a small sample size and limited outcome measures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achenbach, T. M. (2002). Child behavior checklist 1 ½ –5. Burlington: University of Vermont Department of Psychiatry.
Amminger, G. P., Berger, G. E., Schafer, M. R., Klier, C., Friedrich, M. H., & Feucht, M. (2007). Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biological Psychiatry, 61, 551–553.
APA. (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. Washington DC: American Psychiatric Association.
Bell, J. G., Sargent, J. R., Tocher, D. R., & Dick, J. R. (2000). Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins, Leukotrienes, & Essential Fatty Acids, 63, 21–25.
Bell, J. G., MacKinlay, E. E., Dick, J. R., MacDonald, D. J., Boyle, R. M., & Glen, A. C. (2004). Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins, Leukotrienes, & Essential Fatty Acids, 71, 201–204.
Bu, B., Ashwood, P., Harvey, D., King, I. B., Water, J. V., & Jin, L. W. (2006). Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins, Leukotrienes, & Essential Fatty Acids, 74, 215–221.
Centers for Disease Control and Prevention (2007). Surveillance summaries. MMWR [Electronic Version], 56(No. SS-1). Retrieved May 22, 2007.
Fernstrom, J. D. (2000). Can nutrient supplements modify brain function? American Journal of Clinical Nutrition, 71, 1669S–75S.
Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: an update. Journal of Autism & Developmental Disorders, 33, 365–382.
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., et al. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal Clinical Psychiatry, 67, 1954–1967.
Hanson, E., Kalish, L., Bunce, E., Curtis, C., McDaniel, S., Ware, J., et al. (2007). Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. Journal of Autism & Developmental Disorders, 37(4), 628–636.
Harrington, J. W., Rosen, L., & Patrick, P. A. (2006). Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. Developmental and Behavioral Pediatrics, 27, S156–S161.
Horrocks, L. A., & Farooqui, A. A. (2004). Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins, Leukotrienes & Essential Fatty Acids, 70, 361–372.
Johnson, S. M., & Hollander, E. (2003). Evidence that eicosapentaenoic acid is effective in treating autism. Journal of Clinical Psychiatry, 64, 848–849.
Lord, C., Rutter, M., DiLavore, P. C., & Risi, S. (2002). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Los Angeles, Western Psychological Services. Developmental disorders.
Mullen, E. (1995). Mullen scales of early learning. Circle Pines: American Guidance Service.
Newschaffer, C., & Curran, L. (2003). Autism: an emerging public health problem. Public Health Reports, 118, 393–399.
Patrick, L., & Salik, R. (2005). The effect of essential fatty acid supplementation on language development and learning skills in autism and Asperger’s syndrome. Autism Asperger’s Digest, Jan–Feb, 36–37.
Politi, P., Cena, H., Comelli, M., Marrone, G., Allegri, C., Emanuele, E., et al. (2008). Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Archives of Medical Research, 39, 682–685.
Richardson, A. J. (2004). Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins, Leukotrienes, & Essential Fatty Acids, 70, 383–390.
Richardson, A. J., & Puri, B. K. (2002). A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progressive Neuropsychopharmacology Biological Psychiatry, 26, 233–239.
Richardson, A. J., & Montgomery, P. (2005). The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics, 115, 1360–1366.
Ryan, A. S., & Nelson, E. B. (2008). Assessing the effect of docosahexaenoic acid on cognitive functions in healthy preschool children: a randomized placebo-controlled, double-blind study. Clinical Pediatrics, 47, 355–362.
Tapp, J. (2003). Procoder for digital video. Kennedy Center: Vanderbilt University.
Uauy, R., Hoffman, D. R., Peirano, P., Birch, D. G., & Birch, E. E. (2001). Essential fatty acids in visual and brain development. Lipids, 36, 885–895.
Vancassel, S., Durand, G., Barthelemy, C., Lejeune, B., Martineau, J., Guilloteau, D., et al. (2001). Plasma fatty acid levels in autistic children. Prostaglandins Leukotrienes & Essential Fatty Acids, 65, 1–7.
Wainwright, P. E. (2002). Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proceeding of the Nutritional Society, 61, 61–69.
Wong, H. H. L., & Smith, R. G. (2006). Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. Journal of Autism & Developmental Disorders, 36, 901–909.
Acknowledgements
The authors wish to thank Kathleen Colborn for her assistance on this project with respect to data management oversight and assisting with monitoring adherence. The authors would also like to thank all of the participating families.
Acknowledgement of funding
Supported by the John F. & Nancy A. Emmerling Fund / The Pittsburgh Foundation
Financial disclosures
Dr. Cynthia Johnson reported no biomedical financial interest or potential conflicts of interest. Dr. Benjamin Handen disclosed consulting fees for Forest, Bristol Myer Squibb and has research funding from Forest, Bristol Myer Squibb, Johnson and Johnson, Neuropharm, Curemark. Dr. Dr. Michelle Zimmer reported no biomedical financial interest or potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johnson, C.R., Handen, B.L., Zimmer, M. et al. Polyunsaturated Fatty Acid Supplementation in Young Children with Autism. J Dev Phys Disabil 22, 1–10 (2010). https://doi.org/10.1007/s10882-009-9152-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10882-009-9152-x